Disease Applications
Colon Cancer
Colorectal
cancer is the third leading cause of cancer-related deaths in the
United States when men and women are considered separately, and the
second leading cause when both sexes are combined. According to
The American Cancer Society there were 106,100 new cases of colon
cancer and 40,870 new cases of rectal cancer in the United States in
2009.
Etubics colon cancer immunotherapy targets CEA
expressing colon cancer cells. CEA represents an attractive
target antigen for immunotherapy since it is over-expressed in nearly
all colorectal cancers and many pancreatic cancers, 70% of non-small
cell lung cancers and approximately 50% of breast cancers.
Etubics'
colon cancer immunotherapeutic product is currently in Phase I/II
clinical trials at Duke University Medical Center in Durham, N.C. and
Medical Oncology Associates, in Spokane, Wash. Etubics clinical
trials have been funded entirely by the National Cancer Institute
(NCI), through their peer-reviewed granting process. For more
information on Etubics' clinical trial, visit ClinicalTrials.gov.
.